Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zecca

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Acta Neurologica Scandinavica|December 6, 2017
Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuationC Zecca, C G Antozzi, V Torri Clerici, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 14, 2015
Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosisC Zecca, G Disanto, M P Sormani, et al.
Acta Neurologica Scandinavica|March 13, 2018
Pseudobulbar affect as a negative prognostic indicator in amyotrophic lateral sclerosisR Tortelli, S Arcuti, M Copetti, et al.
Multiple Sclerosis and Related Disorders|November 20, 2019
Infusion-related reactions during Natalizumab treatment: Do we still need a post-infusion observation period?R Sacco, G Disanto, I Maraffi, et al.
AJNR. American Journal of Neuroradiology|March 26, 2021
Dedicated 3D-T2-STIR-ZOOMit Imaging Improves Demyelinating Lesion Detection in the Anterior Visual Pathways of Patients with Multiple SclerosisE Pravatà, L Roccatagliata, M P Sormani, et al.
European Journal of Neurology|April 28, 2016
Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of lifeC Zecca, G C Riccitelli, G Disanto, et al.
European Journal of Neurology|November 5, 2024
Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real-word study on aducanumab and lecanemabG Logroscino, D Urso, V Gnoni, et al.
European Journal of Neurology|February 13, 2018
Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosisC Zecca, S Roth, O Findling, et al.
AJNR. American Journal of Neuroradiology|May 26, 2022
Nonlesional Sources of Contrast Enhancement on Postgadolinium "Black-Blood" 3D T1-SPACE Images in Patients with Multiple SclerosisL Danieli, L Roccatagliata, D Distefano, et al.
Acta Neuropathologica|May 8, 2003
Clinical, morphological and immunological evaluation of six patients with dysferlin deficiencyA Prelle, M Sciacco, L Tancredi, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Acta Neurologica Scandinavica|December 6, 2017
Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuationC Zecca, C G Antozzi, V Torri Clerici, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 14, 2015
Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosisC Zecca, G Disanto, M P Sormani, et al.
Acta Neurologica Scandinavica|March 13, 2018
Pseudobulbar affect as a negative prognostic indicator in amyotrophic lateral sclerosisR Tortelli, S Arcuti, M Copetti, et al.
Multiple Sclerosis and Related Disorders|November 20, 2019
Infusion-related reactions during Natalizumab treatment: Do we still need a post-infusion observation period?R Sacco, G Disanto, I Maraffi, et al.
AJNR. American Journal of Neuroradiology|March 26, 2021
Dedicated 3D-T2-STIR-ZOOMit Imaging Improves Demyelinating Lesion Detection in the Anterior Visual Pathways of Patients with Multiple SclerosisE Pravatà, L Roccatagliata, M P Sormani, et al.
European Journal of Neurology|April 28, 2016
Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of lifeC Zecca, G C Riccitelli, G Disanto, et al.
European Journal of Neurology|November 5, 2024
Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real-word study on aducanumab and lecanemabG Logroscino, D Urso, V Gnoni, et al.
European Journal of Neurology|February 13, 2018
Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosisC Zecca, S Roth, O Findling, et al.
AJNR. American Journal of Neuroradiology|May 26, 2022
Nonlesional Sources of Contrast Enhancement on Postgadolinium "Black-Blood" 3D T1-SPACE Images in Patients with Multiple SclerosisL Danieli, L Roccatagliata, D Distefano, et al.
Acta Neuropathologica|May 8, 2003
Clinical, morphological and immunological evaluation of six patients with dysferlin deficiencyA Prelle, M Sciacco, L Tancredi, et al.
Pageof 3